Efficacy and safety of CKD-495 in acute and chronic gastritis: A Phase III superiority clinical trial.

ABSTRACT:

Background

Despite the availability of numerous treatment options, many patients with gastritis experience only partial symptom relief. CKD-495, a newly developed product with the active ingredient extracted from Cinnamomum cassia Presl., has demonstrated anti-inflammatory and antioxidant activity in vitro and an in vivo protective effect against gastric damage by stimulating mucus secretion. This study compared the efficacy and safety of CKD-495 with Artemisiae argyi folium (AAF) for the treatment of acute and chronic gastritis. AAF, a gastric mucosa protective agent that promotes gastric mucosa regeneration, has been used clinically for about 20 years.

Methods

This phase III multicenter, randomized, double-blind, parallel-group trial (ClinicalTrials.gov; NCT04255589) assig

SUBMITTER: Seo SY 

PROVIDER: S-EPMC10713194 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature